Pfizer and French biotech Valneva have announced results from their landmark Phase 3 VALOR trial for the Lyme disease vaccine candidate, PF-07307405 (also called LB6V). The trial demonstrated more than 70% efficacy in preventing Lyme disease and was well tolerated with no safety concerns identified. This 6-valent vaccine targets six different OspA serotypes most commonly found across North America and Europe, working by stopping the infection before it ever leaves the tick.
Job Overview
This notification pertains to the clinical trial results for a new Lyme disease vaccine candidate developed by Pfizer and Valneva. The Phase 3 VALOR (Vaccine Against Lyme for Outdoor Recreationists) study evaluated the efficacy and safety of the vaccine candidate PF-07307405 in preventing Lyme disease.
Conclusion
The results from the VALOR trial create confidence in the vaccine’s potential to protect against a debilitating disease that affects many individuals. The science represents a significant step closer to addressing a genuine unmet medical need for populations in Lyme-endemic areas.
